A citation-based method for searching scientific literature


List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
66

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66


Tight glycemic control may increase regenerative potential of myocardium during acute infarction.
Raffaele Marfella, Ferdinando Carlo Sasso, Federico Cacciapuoti, Michele Portoghese, Maria Rosaria Rizzo, Mario Siniscalchi, Ornella Carbonara, Franca Ferraraccio, Michele Torella, Antonello Petrella,[...]. J Clin Endocrinol Metab 2012
48
33

Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ignatios Ikonomidis, George Pavlidis, John Thymis, Dionysia Birba, Aimilianos Kalogeris, Foteini Kousathana, Aikaterini Kountouri, Konstantinos Balampanis, John Parissis, Ioanna Andreadou,[...]. J Am Heart Assoc 2020
50
33

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
Akira Sezai, Hisakuni Sekino, Satoshi Unosawa, Makoto Taoka, Shunji Osaka, Masashi Tanaka. Cardiovasc Diabetol 2019
32
33

Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.
Miranda Cumpston, Tianjing Li, Matthew J Page, Jacqueline Chandler, Vivian A Welch, Julian Pt Higgins, James Thomas. Cochrane Database Syst Rev 2019
33

Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study.
Concetta Irace, Antonio Cutruzzolà, Martina Parise, Raffaella Fiorentino, Marco Frazzetto, Chiara Gnasso, Francesco Casciaro, Agostino Gnasso. Diab Vasc Dis Res 2020
10
33

Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).
Nur Aisyah Zainordin, Sharifah Faradilla Wan Muhamad Hatta, Fatimah Zaherah Mohamed Shah, Thuhairah Abdul Rahman, Nurhuda Ismail, Zaliha Ismail, Rohana Abdul Ghani. J Endocr Soc 2019
17
33

Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial.
Riobaldo M R Cintra, Alexandre A S Soares, Ikaro Breder, Daniel B Munhoz, Joaquim Barreto, Sheila T Kimura-Medorima, Pamela Cavalcante, Renata Zanchetta, Jessica Cunha Breder, Camila Moreira,[...]. Diabetol Metab Syndr 2019
8
33

Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study.
Joseph Yeboah, John R Crouse, Fang-Chi Hsu, Gregory L Burke, David M Herrington. Circulation 2007
676
33


Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
Ikaro Breder, Jessica Cunha Breder, Isabella Bonilha, Daniel B Munhoz, Sheila T Kimura Medorima, Daniela C Oliveira, Helison R do Carmo, Camila Moreira, Anatol Kontush, Francesca Zimetti,[...]. Ther Adv Chronic Dis 2020
5
33

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.
Hong Sun, Pouya Saeedi, Suvi Karuranga, Moritz Pinkepank, Katherine Ogurtsova, Bruce B Duncan, Caroline Stein, Abdul Basit, Juliana C N Chan, Jean Claude Mbanya,[...]. Diabetes Res Clin Pract 2022
148
33

Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.
Eirini Papadopoulou, Charalampos Loutradis, Glykeria Tzatzagou, Kalliopi Kotsa, Ioanna Zografou, Ioanna Minopoulou, Marietta P Theodorakopoulou, Apostolos Tsapas, Asterios Karagiannis, Pantelis Sarafidis. J Hypertens 2021
15
33

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome.
Zeeshan Javed, Maria Papageorgiou, Leigh A Madden, Alan S Rigby, Eric S Kilpatrick, Stephen L Atkin, Thozhukat Sathyapalan. Endocr Connect 2020
8
33

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
33


Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
Sin-Hee Park, Eugenia Belcastro, Hira Hasan, Kensuke Matsushita, Benjamin Marchandot, Malak Abbas, Florence Toti, Cyril Auger, Laurence Jesel, Patrick Ohlmann,[...]. Cardiovasc Diabetol 2021
17
33

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara,[...]. Intern Med 2018
41
33

SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice.
Meghan F Hogan, Daryl J Hackney, Alfred C Aplin, Thomas O Mundinger, Megan J Larmore, Joseph J Castillo, Nathalie Esser, Sakeneh Zraika, Rebecca L Hull. J Endocrinol 2021
7
33

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. Eur J Pharmacol 2017
28
33

Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi,[...]. Cardiovasc Diabetol 2021
12
33

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Takahiro Sawada, Kenzo Uzu, Naoko Hashimoto, Tetsuari Onishi, Tomofumi Takaya, Akira Shimane, Yasuyo Taniguchi, Yoshinori Yasaka, Takeshi Ohara, Hiroya Kawai. J Atheroscler Thromb 2020
18
33

Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes.
Ferdinando Carlo Sasso, Luca Rinaldi, Nadia Lascar, Aldo Marrone, Pia Clara Pafundi, Luigi Elio Adinolfi, Raffaele Marfella. J Diabetes Res 2018
53
33

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
Nunzia D'Onofrio, Celestino Sardu, Maria Consiglia Trotta, Lucia Scisciola, Fabrizio Turriziani, Franca Ferraraccio, Iacopo Panarese, Lella Petrella, Mara Fanelli, Piero Modugno,[...]. Mol Metab 2021
16
33

Effect of pioglitazone on endothelial function in impaired glucose tolerance.
C E Quinn, C J Lockhart, P K Hamilton, C M Loughrey, G E McVeigh. Diabetes Obes Metab 2010
15
33

Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes.
Alexios S Antonopoulos, Gerasimos Siasos, Dimitris Tousoulis. JAMA Cardiol 2017
7
33


Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Andrei C Sposito, Ikaro Breder, Alexandre A S Soares, Sheila T Kimura-Medorima, Daniel B Munhoz, Riobaldo M R Cintra, Isabella Bonilha, Daniela C Oliveira, Jessica Cunha Breder, Pamela Cavalcante,[...]. Cardiovasc Diabetol 2021
12
33

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Kayoko Ikehara, Eiichiro Kanda, Hiroshi Uchino, Takahisa Hirose. Cardiovasc Diabetol 2017
125
33

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
18
33

Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction.
Rio P Juni, Rushd Al-Shama, Diederik W D Kuster, Jolanda van der Velden, Henrike M Hamer, Marc G Vervloet, Etto C Eringa, Pieter Koolwijk, Victor W M van Hinsbergh. Kidney Int 2021
16
33


Epidemiology of Diabetes Mellitus and Cardiovascular Disease.
Diana Glovaci, Wenjun Fan, Nathan D Wong. Curr Cardiol Rep 2019
107
33

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.
Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. Cardiovasc Diabetol 2017
184
33


Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Alvaro Garcia-Ropero, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Ariana P Vargas-Delgado, Eduardo J Flores-Umanzor, Javier Sanz,[...]. JACC Cardiovasc Imaging 2021
52
33


Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.
Afnan S Alshnbari, Sophie A Millar, Saoirse E O'Sullivan, Iskandar Idris. Diabetes Ther 2020
26
33

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Mojca Lunder, Miodrag Janić, Miha Japelj, Andrej Juretič, Andrej Janež, Mišo Šabovič. Cardiovasc Diabetol 2018
46
33

The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature.
Anna Solini, Marta Seghieri, Livia Giannini, Edoardo Biancalana, Federico Parolini, Chiara Rossi, Angela Dardano, Stefano Taddei, Lorenzo Ghiadoni, Rosa Maria Bruno. J Clin Endocrinol Metab 2019
27
33



Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
Laween Uthman, Anna Homayr, Rio P Juni, Eva L Spin, Raphaela Kerindongo, Marleen Boomsma, Markus W Hollmann, Benedikt Preckel, Pieter Koolwijk, Victor W M van Hinsbergh,[...]. Cell Physiol Biochem 2019
68
33

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz, Josep Redón, Alberto Zanchetti, Michael Böhm, Thierry Christiaens, Renata Cifkova, Guy De Backer, Anna Dominiczak,[...]. J Hypertens 2013
33


Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann,[...]. Cardiovasc Diabetol 2020
37
33

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Detmar Kolijn, Steffen Pabel, Yanna Tian, Mária Lódi, Melissa Herwig, Albino Carrizzo, Saltanat Zhazykbayeva, Árpád Kovács, Gábor Á Fülöp, Inês Falcão-Pires,[...]. Cardiovasc Res 2021
62
33

Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial.
Atsushi Tanaka, Michio Shimabukuro, Noritaka Machii, Hiroki Teragawa, Yosuke Okada, Kosuke R Shima, Toshinari Takamura, Isao Taguchi, Itaru Hisauchi, Shigeru Toyoda,[...]. Diabetes Care 2019
27
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.